Predictors of Stroke Recurrence After Initial Diagnosis of Cervical Artery Dissection
Abstract
Objective Patients with cervical artery dissection (CAD) are at increased ischemic stroke risk. We aimed to identify characteristics that are associated with increased risk of ischemic stroke following initial presentation of CAD and to evaluate the differential impact of anticoagulant versus antiplatelet therapy in these high-risk individuals.
Methods This was a secondary analysis of the Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection (STOP-CAD) study, a multicenter retrospective observational study. The primary outcome was subsequent ischemic stroke by day 180 after diagnosis. Patient characteristics were compared between those with vs. without subsequent ischemic stroke. Significant predictors were identified using stepwise Cox regression. Associations between subsequent ischemic stroke risk and antithrombotic therapy type in high-risk patients were explored using adjusted Cox regression.
Results 4,023 patients (mean age 47.4 years; 44.5% were women) were included. By day 180, 5.3% experienced a subsequent ischemic stroke. In adjusted Cox regression, factors associated with increased subsequent ischemic stroke risk were prior ischemic stroke (aHR 7.31, 95% CI 1.61-33.13, p=0.010), presentation within seven days from symptoms, (aHR 3.04, 95% CI 1.04-8.91, p=0.043), infarct on imaging (aHR 9.85, 95% CI 3.65-26.58, p<0.001), and occlusive dissection (aHR 2.34, 95% CI 1.03-5.34, p=0.043). Only patients with occlusive dissection had reduced subsequent ischemic stroke risk with anticoagulation versus antiplatelets (HR 0.37; 95% CI 0.15-0.89, p=0.03).
Interpretation This study identified several predictors of subsequent ischemic stroke among patients with CAD but only patients with occlusive dissection demonstrated a benefit from anticoagulation. These findings require validation by meta-analyses of prior studies.
Competing Interest Statement
CHN received funding from German Center for cardiovascular Research (DZHK) and German Center for neurodegenerative diseases (DZNE). CHN reports honoraria for lectures and/or speakers bureau from Abbott, Alexion, Astra Zeneca, BMS, Daiichi Sankyo, Novartis, Pfizer, Portola and Takeda. TNN reports advisory board for Brainomix, Aruna Bio; Associate Editor of Stroke.
Funding Statement
This study was not funded.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This analysis was conducted in accordance with the ethical guidelines of the original STOP-CAD study, which received Institutional Review Board (IRB) approval. As this is a secondary analysis of de-identified data, additional IRB approval was waived by the Lifespan IRB. Aggregate data will be shared upon reasonable request to the STOP-CAD principal investigator.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
This analysis was conducted in accordance with the ethical guidelines of the original STOP-CAD study, which received Institutional Review Board (IRB) approval. As this is a secondary analysis of de-identified data, additional IRB approval was waived by the Lifespan IRB. Aggregate data will be shared upon reasonable request to the STOP-CAD principal investigator.
Subject Area
- Addiction Medicine (376)
- Allergy and Immunology (692)
- Anesthesia (185)
- Cardiovascular Medicine (2781)
- Dermatology (237)
- Emergency Medicine (418)
- Epidemiology (12436)
- Forensic Medicine (10)
- Gastroenterology (787)
- Genetic and Genomic Medicine (4303)
- Geriatric Medicine (397)
- Health Economics (706)
- Health Informatics (2778)
- Health Policy (1030)
- Hematology (371)
- HIV/AIDS (883)
- Medical Education (406)
- Medical Ethics (113)
- Nephrology (455)
- Neurology (4080)
- Nursing (218)
- Nutrition (604)
- Oncology (2157)
- Ophthalmology (609)
- Orthopedics (253)
- Otolaryngology (313)
- Pain Medicine (257)
- Palliative Medicine (79)
- Pathology (481)
- Pediatrics (1152)
- Primary Care Research (475)
- Public and Global Health (6682)
- Radiology and Imaging (1457)
- Respiratory Medicine (889)
- Rheumatology (425)
- Sports Medicine (354)
- Surgery (467)
- Toxicology (57)
- Transplantation (196)
- Urology (172)